Lomustine
- Generic Name
- Lomustine
- Brand Names
- Ceenu, Gleostine
- Drug Type
- Small Molecule
- Chemical Formula
- C9H16ClN3O2
- CAS Number
- 13010-47-4
- Unique Ingredient Identifier
- 7BRF0Z81KG
- Background
An alkylating agent of value against both hematologic malignancies and solid tumors.
- Indication
For the treatment of primary and metastatic brain tumors as a component of combination chemotherapy in addition to appropriate surgical and/or radiotherapeutic procedures. Also used in combination with other agents as secondary therapy for the treatment of refractory or relapsed Hodgkin's disease.
- Associated Conditions
- Metastatic Brain Tumors, Primary Brain Neoplasm, Refractory Hodgkin Lymphoma
- Associated Therapies
- -
Ph 1/2 CTO With Lomustine for Bevacizumab-Naive Recurrent Glioma
- Conditions
- Interventions
- First Posted Date
- 2013-11-20
- Last Posted Date
- 2016-08-04
- Lead Sponsor
- Annick Desjardins
- Target Recruit Count
- 9
- Registration Number
- NCT01989052
- Locations
- 🇺🇸
The Preston Robert Tisch Brain Tumor Center at Duke, Durham, North Carolina, United States
Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme
- Conditions
- Interventions
- First Posted Date
- 2013-09-04
- Last Posted Date
- 2020-12-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 35
- Registration Number
- NCT01934361
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸MD Anderson Cancer Center/University of Texas, Houston, Texas, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
A Comparison of Continuous Bevacizumab (Avastin) Treatment or Placebo in Addition to Lomustine Followed by Standard of Care After Disease Progression in Participants With Glioblastoma
- Conditions
- Interventions
- First Posted Date
- 2013-05-23
- Last Posted Date
- 2018-04-30
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 296
- Registration Number
- NCT01860638
- Locations
- 🇦🇹
Medizinische Universität Graz; Universitätsklinik für Neurologie, Graz, Austria
🇷🇴Institutul Oncologic Prof. Dr. Al. Trestioreanu Bucuresti, Bucuresti, Romania
🇦🇹Medizinische Universität Wien; Univ.Klinik für Innere Medizin I - Abt. für Onkologie, Wien, Austria
Intravenous Chemotherapy or Oral Chemotherapy in Treating Patients With Previously Untreated Stage III-IV HIV-Associated Non-Hodgkin Lymphoma
- Conditions
- AIDS-related Diffuse Mixed Cell LymphomaAIDS-related Peripheral/Systemic LymphomaAIDS-related Lymphoblastic LymphomaAIDS-related Small Noncleaved Cell LymphomaStage IV AIDS-related LymphomaAIDS-related Diffuse Large Cell LymphomaStage III AIDS-related LymphomaAIDS-related Diffuse Small Cleaved Cell LymphomaAIDS-related Immunoblastic Large Cell Lymphoma
- Interventions
- First Posted Date
- 2013-01-25
- Last Posted Date
- 2022-10-10
- Lead Sponsor
- AIDS Malignancy Consortium
- Target Recruit Count
- 7
- Registration Number
- NCT01775475
- Locations
- 🇿🇼
University of Zimbabwe College of Health Sciences, Harare, Zimbabwe
🇰🇪Moi Teaching and Referral Hospital, Eldoret, Kenya
A Dose-Escalation Study in Participants With Recurrent Malignant Glioma
- First Posted Date
- 2012-09-10
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 66
- Registration Number
- NCT01682187
- Locations
- 🇪🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sevilla, Spain
A Study in Recurrent Glioblastoma (GB)
- Conditions
- Interventions
- First Posted Date
- 2012-04-20
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 151
- Registration Number
- NCT01582269
- Locations
- 🇪🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barcelona, Spain
A Clinical Trial to Assess the Safety & Efficacy of the Treatment of Patients With Metastasis From Malignant Melanoma - Treatment Consists of the Substances Lomustine (Capsules) & Cytarabine (Injected Into an Area Near the Spinal Cord), Accompanied by Radiotherapy of the Brain
- First Posted Date
- 2012-03-27
- Last Posted Date
- 2016-04-19
- Lead Sponsor
- University Hospital, Bonn
- Target Recruit Count
- 1
- Registration Number
- NCT01563614
- Locations
- 🇩🇪
Neurologische Universitaetsklinik Bonn, Bonn, Germany
Bevacizumab and Lomustine for Recurrent GBM
- First Posted Date
- 2011-02-07
- Last Posted Date
- 2021-02-15
- Target Recruit Count
- 592
- Registration Number
- NCT01290939
- Locations
- 🇳🇱
Erasmus MC - Daniel den Hoed Cancer Center, Rotterdam, Netherlands
🇳🇱Medisch Centrum Haaglanden - Westeinde, Den Haag, Netherlands
Standard Dose Bevacizumab Versus Low Dose Bevacizumab Plus Lomustine (CCNU) for Recurrent Glioblastoma Multiforme (GBM)
- Conditions
- Interventions
- First Posted Date
- 2010-02-11
- Last Posted Date
- 2020-03-17
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 83
- Registration Number
- NCT01067469
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Methotrexate-based Chemo-immunotherapy Followed by Maintenance Therapy for Patients > 65 Years With Central Nervous System (CNS)-Lymphoma
- Conditions
- First Posted Date
- 2009-10-05
- Last Posted Date
- 2009-10-05
- Lead Sponsor
- University Hospital Freiburg
- Target Recruit Count
- 56
- Registration Number
- NCT00989352
- Locations
- 🇩🇪
University Medical Center Freiburg, Dept. of Internal Medicine I - Hematology and Oncology, Freiburg, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.